Brain tumors are difficult to treat in part because of the blood-brain barrier, the need to protect healthy and sensitive tissue surrounding tumors, and the limits of existing therapies. While there have been great advances in other types of cancer, there’s been relatively little progress in treating these CNS tumors. Plus Therapeutic is developing targeted radiotherapies that provide high doses of radiation directly into the tumor with a catheter. The approach enables the delivery of higher doses of radiation while minimizing exposure to healthy brain cells. We spoke to Marc Hedrick, president and CEO of Plus Therapeutics, about the challenges of treating brain tumors, the limitations of current therapies, and why the company’s targeted radiotherapies have the potential to create better outcomes for patients.